Zika Virus Antibody, IgM
Use
Presumptive qualitative detection of Zika virus IgM antibodies in human sera collected from individuals meeting CDC Zika virus clinical criteria (eg, a history of clinical signs and symptoms associated with Zika virus infection) and/or CDC Zika virus epidemiological criteria (eg, history of residence in or travel to a geographic region with active Zika transmission at the time of travel, or other epidemiological criteria for which Zika virus testing may be indicated).
Special Instructions
Not provided.
Limitations
The test results may include false-negative and false-positive results. False negatives may occur if specimens are collected too early or too late relative to symptom onset, or if there are issues with specimen collection, storage, or transport. False positives can occur due to cross-reactivity with other flaviviruses like Dengue, or non-specific reactions. The assay has not been studied in pediatric populations and is not recommended for blood or plasma donor screening or general population screening.
Methodology
Immunoassay (CLIA)
Biomarkers
Zika Virus IgM
Antibody
LOINC Codes
- 80824-6 - ZIKV IgM SerPl Ql IA
- 80824-6 - ZIKV IgM SerPl Ql IA
Result Turnaround Time
2-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL
Container
Gel-barrier tube or red-top tube or serum transfer tube
Collection Instructions
Blood should be collected aseptically by venipuncture. Samples must be allowed to clot and centrifuged and separated from the clot as soon as possible.
Storage Instructions
Refrigerate.
Causes for Rejection
Grossly hemolyzed or lipemic samples, samples with particulate matter, or samples with obvious microbial contamination.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 24 hours |
| Refrigerated | 7 days |
| Frozen | >7 days |
Other tests from different labs that may be relevant